newsfilter
← Latest News
PR Newswire·

PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

SALT LAKE CITY, May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers